<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443820</url>
  </required_header>
  <id_info>
    <org_study_id>CSFO327N2302</org_study_id>
    <nct_id>NCT00443820</nct_id>
  </id_info>
  <brief_title>Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy, safety and tolerability of a topical
      formulation of terbinafine solution applied daily in patients with toenail fungus. This trial
      will study patients with mild to moderate toenail fungus disease of the big toenail and their
      responses to two treatment durations, 24 or 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as &quot;Yes&quot; if:
If mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail &quot;No&quot; if otherwise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (placebo) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (placebo) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbinafine</intervention_name>
    <description>Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle (placebo) once daily for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbinafine</intervention_name>
    <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle (placebo) once daily for 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females 12 - 75 years of age

          -  Fungal toenail infection of one or both of the large (great) toenails

          -  The nail infection must be due to a dermatophyte, (mixed infections dermatophyte and
             non-dermatophyte] are not allowed)

        Exclusion Criteria:

          -  Target foot must not have severe plantar (moccasin) tinea pedis that would require
             systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be
             treated with terbinafine prior to baseline or at any time during the trial. Other
             topical treatments for athlete's foot may be recommended at the discretion of the
             investigator.

          -  Subjects must not have abnormalities of the nail that could prevent a normal appearing
             nail if clearing of infection is achieved

          -  No administration of systemic antifungal medications within 6 months prior to
             screening visit

          -  No application of prescription topical antifungal medications for toenail fungus
             within 3 months or other commercially available topical medications for toenail fungus
             applied directly to the toenails within 1 month prior to screening visit

          -  No professional pedicures or application of any nail polish product or nail cosmetic
             to the toenails after the screening visit

          -  Known pregnancy or lactation at time of enrollment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Fred D. Youngswick</name>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Larry Doehring</name>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <zip>80234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Robert P. Dunne</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Mark Ling</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jesse Plasencia</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. John Mallory</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jeffrey Conrow</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Michael Kaye</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Max Weisfeld</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Linda Stein-Gold</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anna Glaser</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Richard Scher</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Joseph Jorrizo</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anne Lucky</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rich Phoebe</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Patricia Westmorland</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David Horowitz</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jay Lifshen</name>
      <address>
        <city>Irving,</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Richard Pollak</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Patrick Agnew</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Investigative Site</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various cities</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <results_first_submitted>January 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2011</results_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Toenail fungus</keyword>
  <keyword>Onychomycosis</keyword>
  <keyword>Nail fungus</keyword>
  <keyword>Toenail fungal infection</keyword>
  <keyword>Tinea unguium</keyword>
  <keyword>Dermatophytes</keyword>
  <keyword>Foot dermatoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This randomized, double -blind, vehicle -controlled, multicenter, parallel group study was designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine hydrogen chloride 10% topical solution (TTS10%) applied daily in patients with toenail onychomycosis. Started 07 DEC 2006 and ending 27 JUN 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Terbinafine 24 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Vehicle 24 Weeks</title>
          <description>Vehicle (placebo) for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Terbinafine 48 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
        </group>
        <group group_id="P4">
          <title>Vehicle 48 Weeks</title>
          <description>Vehicle (placebo) for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="131">Participants who received study drug and had at least one post-baseline safety assessment.</participants>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="111">A participant from this gr. discont'ed due to renal failure, was counted as an AE and also as a SAE.</participants>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terbinafine 24 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Vehicle 24 Weeks</title>
          <description>Vehicle (placebo) for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Terbinafine 48 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>Vehicle 48 Weeks</title>
          <description>Vehicle (placebo) for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="128"/>
            <count group_id="B5" value="526"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks</title>
        <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 Weeks</title>
            <description>Vehicle (placebo) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 Weeks</title>
            <description>Vehicle (placebo) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks</title>
          <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
          <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-1.82" upper_limit="3.29"/>
                    <measurement group_id="O2" value="0.77" lower_limit="-1.82" upper_limit="3.29"/>
                    <measurement group_id="O3" value="2.96" lower_limit="0.10" upper_limit="5.82"/>
                    <measurement group_id="O4" value="0" lower_limit="0.10" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks</title>
        <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 Weeks</title>
            <description>Vehicle (placebo) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 Weeks</title>
            <description>Vehicle (placebo) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks</title>
          <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.</description>
          <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.04" lower_limit="1.54" upper_limit="16.23"/>
                    <measurement group_id="O2" value="6.15" lower_limit="1.54" upper_limit="16.23"/>
                    <measurement group_id="O3" value="22.22" lower_limit="6.00" upper_limit="22.82"/>
                    <measurement group_id="O4" value="7.81" lower_limit="6.00" upper_limit="22.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks</title>
        <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as
Yes” if:
If mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail
No” if otherwise</description>
        <time_frame>52 weeks</time_frame>
        <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 Weeks</title>
            <description>Vehicle (placebo) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 Weeks</title>
            <description>Vehicle (placebo) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks</title>
          <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as
Yes” if:
If mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail
No” if otherwise</description>
          <population>Intent to treat (ITT) population, Last observation carried forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01"/>
                    <measurement group_id="O2" value="0.77"/>
                    <measurement group_id="O3" value="5.93"/>
                    <measurement group_id="O4" value="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</title>
        <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.</description>
        <time_frame>52 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 Weeks</title>
            <description>Vehicle (placebo) for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 Weeks</title>
            <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 Weeks</title>
            <description>Vehicle (placebo) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</title>
          <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.</description>
          <population>Safety Population</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study drug discontinued due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Safety population consisting of all participants who had at least one dose of study drug and had at least one post-baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Terbinafine 24 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Vehicle 24 Weeks</title>
          <description>Vehicle (placebo) for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Terbinafine 48 Weeks</title>
          <description>Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks</description>
        </group>
        <group group_id="E4">
          <title>Vehicle 48 Weeks</title>
          <description>Vehicle (placebo) for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

